Skip to main content

Drug Interactions between amobarbital and hemin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

amobarbital hemin

Applies to: amobarbital and hemin

GENERALLY AVOID: Coadministration with drugs that are capable of increasing the activity of delta-aminolevulinic acid synthetase (e.g., estrogens, barbiturates, steroid metabolites, rifampin) may negate the pharmacologic effect of hemin. In the treatment of porphyria, hemin is thought to limit the rate of porphyrin/heme biosynthesis by inhibiting delta-aminolevulinic acid synthetase, thus any induction of this enzyme would be expected to counteract the therapeutic effect of hemin.

MANAGEMENT: Drugs capable of increasing the activity of delta-aminolevulinic acid synthetase should be avoided during hemin therapy.

References (5)
  1. (2001) "Product Information. Panhematin (hemin)." Recordati Rare Diseases Inc
  2. (2023) "Product Information. Normosang (hemin)." Imported (France)
  3. Pozo OJ, marcos j, Fabregat A, Ventura R, Casals G, Aguilera P, Segura J, To-Figueras J (2014) "Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study" Orphanet Journal of Rare Diseases, 9, p. 54
  4. anderson ke, Bloomer JR, Bonkovsky HL, Desnick RJ, kushner jp, pierach ca, pimstone nr (2005) Recommendations for the Diagnosis and Treatment of the Acute Porphyrias https://www.acpjournals.org/doi/full/10.7326/0003-4819-142-6-200503150-00010
  5. Herrick AL, mccoll ke, moore mr, Brodie MJ, Adamson AR, Goldberg A (1989) "Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity" Br J Clin Pharmacol, 27, 491- 497

Drug and food interactions

Major

amobarbital food

Applies to: amobarbital

GENERALLY AVOID: Concurrent acute use of barbiturates and ethanol may result in additive CNS effects, including impaired coordination, sedation, and death. Tolerance of these agents may occur with chronic use. The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.

MANAGEMENT: The combination of ethanol and barbiturates should be avoided.

References (5)
  1. Gupta RC, Kofoed J (1966) "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J, 94, p. 863-5
  2. Misra PS, Lefevre A, Ishii H, Rubin E, Lieber CS (1971) "Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats." Am J Med, 51, p. 346-51
  3. Saario I, Linnoila M (1976) "Effect of subacute treatment with hypnotics, alone or in combination with alcohol, on psychomotor skills related to driving." Acta Pharmacol Toxicol (Copenh), 38, p. 382-92
  4. Stead AH, Moffat AC (1983) "Quantification of the interaction between barbiturates and alcohol and interpretation of fatal blood concentrations." Hum Toxicol, 2, p. 5-14
  5. Seixas FA (1979) "Drug/alcohol interactions: avert potential dangers." Geriatrics, 34, p. 89-102

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer